Glioblastoma multiforme is a highly invasive tumor bearing a dismal prognosis. Experimental strategies that focus on the specific biological cues governing the invasive capacity of these tumors may hold significant therapeutic promise. In this context, we describe the in vitro and in vivo association of the cell surface chemokine receptor, CXCR4, with the development of an invasive phenotype in malignant glioblastoma. We demonstrate that invasive populations of glioma cells overexpress CXCR4 at the message and protein levels, and that this expression ranges from 25-to 89-fold higher than that found in noninvasive tumor cells. Furthermore, neutralization of CXCR4 significantly impairs the in vitro invasive capacity of malignant glial cells. In addition, glioma cells secrete CXCL12 and demonstrate robust invasive capacity toward a CXCL12 gradient in vitro. These findings underscore the importance of CXCR4 as a potential therapeutic target for the treatment of invasive glioblastoma.
Despite significant advances in surgical techniques, imaging technology, and chemo-and radiotherapeutic regimens, the survival for patients with glioblastoma multiforme remains dismal, with a 2 year survival rate approaching zero (Surawicz et al., 1998) . The aggressiveness of these neoplasms and their refractoriness to current therapies stems to a significant extent from their highly invasive nature. These tumors spawn numerous microscopic satellites that infiltrate normal brain parenchyma, often migrating to significant distance from the primary tumor mass. Surgical resection frequently leaves behind these dispersed tumor foci, which subsequently escape adjuvant radiation and chemotherapy eventually leading to tumor regrowth and patient death.
The development of a viable therapy for glioblastoma will, therefore, require a detailed understanding of the factors that govern the invasive capacity of these cells in order to develop targeted strategies to minimize tumor cell invasiveness. In this report, we now describe the contribution of the C-X-C Chemokine Receptor 4 (CXCR4) to glioma cell dispersal thereby identifying this receptor as a promising candidate for directed therapy aimed towards inhibiting glioma cell invasion.
The ability of neoplastic cells to infiltrate adjacent healthy tissue and disperse from the principal site of tumor formation involves a complex and highly orchestrated series of biological events. Although numerous signaling mechanisms have been implicated in facilitating this process, there has been a growing recognition that the dispersal of cancer is a nonrandom, selective process likely governed by directional migratory cues (Strieter, 2001) . In this context, chemokines, a family of secreted and highly chemotactic small peptide ligands known primarily for their potent migratory effects on immune cells, have received increasing attention as mediators of tumor cell invasiveness and metastasis. Although there are, to date, over 50 known members of the chemokine ligand family, one particular sub-group, the CXC chemokines have been the subject of significant focus in the setting of cancer. In particular, CXCL12 (also known as stromal derived factor-1, SDF-1) and its cell surface receptor CXCR4 have been shown to mediate tumor cell dispersal in a wide range of malignancies including breast tumors (Muller et al., 2001; Fernandis et al., 2004) , colon carcinoma (Zeelenberg et al., 2003) , pancreatic cancer (Mori et al., 2004) , melanoma (Bartolome et al., 2004) , lung cancer (Belperio et al., 2004) , and prostate tumors (Singh et al., 2004) .
Based on the known association between CXCR4 expression and tumor cell dispersal in a variety of cancers, we hypothesized that the expression of this receptor by glioma cells may be associated with their invasive potential. To investigate this, we analysed invasive glioma cells from multiple glial tumor cell lines as well as primary human GBM explants and compared the expression of CXCR4 in these cells to noninvasive cells derived from the same tumors. We observed that in an intracranial rat C6 glioma model, neoplastic cells isolated from in vivo infiltrative tumor foci by means of laser capture microdissection (LCM) expressed significantly more CXCR4 message compared to noninvasive tumor cells harvested simultaneously from the nonnecrotic tumor core (Figure 1) . We then utilized an in vitro matrigel invasion assay and found that CXCR4 was also significantly overexpressed in invasive human glioma cells derived from several glioblastoma tumor lines at both the message and protein levels, and that this expression ranged from 25-to 89-fold higher than that found in noninvasive tumor cells (Figure 2) . Additionally, invasive U118MG glioma cells also demonstrated significantly greater expression (64 fold higher) of CXCL12 ligand as compared to noninvasive tumor cells, and multiple glioma cell lines as well as a primary GBM explant demonstrated secretion of CXCL12 protein into culture supernatant in vitro, at levels previously reported to be sufficient for the induction of CXCR4 signaling in glioma cells (Barbero et al., 2003) . These results demonstrate a clear association between CXCR4 overexpression and an invasive glioma phenotype and indicate that tumor cells, themselves may serve as an autocrine/paracrine source of CXCL12 ligand, although significant expression of CXCL12 by tumor infiltrating stromal cells and endothelial cells has also been reported in a variety of cancers (Rubin et al., 2003; Orimo et al., 2005) . In order to confirm a direct link between CXCR4 signaling and glioma cell invasion, we then utilized an in vitro matrigel invasion system to assess whether inhibition of CXCR4 using a neutralizing antibody would abrogate the invasive capacity of tumor cells. We observed that in three of the five glioma lines analysed, including one of two primary human GBM explants, the addition of a CXCR4 neutralizing antibody significantly impaired the ability of tumor cells to invade across a matrigel matrix as compared to analogous cells treated with a similar Figure 3a ). We subsequently confirmed using flow cytometry that the two nonresponsive glioma lines expressed negligible levels of CXCR4 protein compared to the three tumors in which notable abrogation of invasive capacity was achieved (data not shown). Subsequently, we tested an alternate method of neutralizing CXCR4 function, involving the transfection of glioma cells with CXCR4 targeted siRNA duplexes. We verified the ability of siRNA transfection to abrogate receptor expression in glioma cell lines and then demonstrated that, similar to antibody-mediated neutralization, siRNA silencing of CXCR4 also inhibited the ability of glioma cells to migrate across a matrigel matrix towards a CXCL12 gradient in vitro (Figure 3b and c). These results clearly demonstrate that the functional neutralization of CXCR4 receptors on the surface of glioma cells may be a promising means of inhibiting their invasive potential. Given the significant treatment challenge posed by invasive glioblastoma, there has been an increasing focus on deciphering the biological cues that govern the ability of these tumors to disseminate. Although an exhaustive array of factors have been implicated in facilitating tumor cell migration, the recent description of chemokine receptors, particularly CXCR4, as being critical to the metastatic and invasive capacity of a wide range of tumors (Muller et al., 2001; Zeelenberg et al., 2003; Bartolome et al., 2004; Belperio et al., 2004; Fernandis et al., 2004; Singh et al., 2004 ) makes this cell surface molecule an attractive candidate as a facilitator of glioma cell dispersal. Several studies have analysed the expression of CXCR4 by glioma. An initial report by Oh et al. (2001) analysed basal CXCR4 mRNA levels using an early and insensitive RPA hybridization assay in two defined cell lines -CRT-MG and U87MG. They found basal CXCR4 expression to be low but noted that, however, increased CXCR4 levels could be induced by exposure of glioma cell cultures to TNF-a, IL-1b. Subsequently, Zhou et al. (2002) utilized similar methodology, documented that 13 of 16 established glioma cell lines, six of six primary glioblastomas demonstrated expression of CXCR4. Additionally, they described that this expression was of functional significance as treatment of CXCR4 positive glioma cells with CXCL12 ligand resulted in ERK phosphorylation, a known downstream event involved in CXCR4 signaling. More significant have been recent reports from Barbero et al. (2003) and Rubin et al. (2003) which have comprehensively demonstrated the expression of CXCR4 across a broad range of human glioma cell lines and primary glioblastomas. Barbero et al. (2003) also documented that the autocrine production of CXCL12 by glioma cells acted through tumor cell surface CXCR4 to support glioma proliferation. These detailed findings were in contrast to an earlier report that suggested that, despite expression of CXCR4, gliomas expressed little CXCL12 (Zhou et al., 2002) . In this study, we too have now documented the ability of glioma cells to secrete CXCL12 protein into their culture supernatant in vitro, at levels consistent with those reported by Barbero et al. (2003) . Rubin et al. (2003) have since demonstrated that the use of the pharmacological CXCR4 inhibitor AMD3100 significantly impairs glioma cell proliferation in vitro and in vivo. Additionally, they describe the ability of this CXCR4 antagonist to inhibit glioma cell chemotaxis towards a CXCL12 gradient in vitro. It is important to note, however, that the chemotaxis results they report were derived from the use of a Boyden chamber assay, which does not truly Figure 1 Invasive C6 glioma cells overexpress CXCR4. Intracranial C6 gliomas were established in adult Sprague Dawley rats using methodology detailed earlier (Ehtesham et al., 2002) . (a) Laser capture microdissection: 14 days following tumor implantation, tumor bearing brains were harvested, cryo-sectioned, and prepared for LCM. A hematoxylin counterstain allowed clear visualization of the core non-necrotic tumor as well as hypercellular infiltrating tumor satellites (T, demarcated by arrow heads) that were interspersed with normal brain parenchyma. Using an Arcturus PixCell II laser capture microdissection system (Arcturus; Mountain View, CA), cells were collected by laser capture from the core tumor as well as infiltrative tumor pockets, and were pooled from 15 to 20 sections each from 2 to 3 tumor bearing animals -the experiment was repeated four times. Representative images from panels on the right demonstrate captured cells on thermoplastic film. (b) Quantitative real-time PCR: Samples were processed for RNA extraction (RNAqeous Micro Kit -Ambion; Austin, TX) followed by reverse transcription (Superscript III system -Invitrogen; Carlsbad, CA). Equal volumes of cDNA were then used for qPCR using CXCR4 and 18s ribosomal RNA specific primers (Rat CXCR4 forward: CGTCGTGCACAAGTGGATCT; Rat CXCR4 reverse: GTTCAGGCAACAGTGGAAGAAG) and FAM labeled Taqman-MGB probes (Rat CXCR4: 6FAM-CATCACGGAGGCCCTC) (Sequences for 18sRNA are proprietary and were obtained from Applied Biosystems; Foster City, CA). Using a Taqman PCR Master mix (Applied biosystems), all samples were amplified in duplicate in a Biorad s I-cycler using the following conditions: Activation of Taq polymerase for 10 min at 951C followed by 45 cycles of annealing for 15 s at 951C and extension for 45 s at 601C. Graph illustrates detected increases in fluorescence emission with progressive amplification of templates (x-axis represents PCR cycles). A threshold cycle (C t ) for each sample was calculated based on the moment that fluorescence emission for that sample exceeded a threshold baseline. To normalize for differing cDNA quantities at the start of the reaction, mean C t values for CXCR4 were normalized against mean C t values for 18sRNA from the same sample (C t CXCR4 -C t 18sRNA ¼ C t diff ) (Rationale for calculation described by us earlier in detail (Ehtesham et al., 2003) ). The raw data from one of the four experimental replicates is presented in tabular form next to its corresponding amplification plot. There was a difference of five cycles between the C t diff values for infiltrating tumor versus core noninvasive tumor. Based on the established premise that PCR amplification follows a natural logarithmic progression, a one cycle difference in C t diff values translates into a twofold difference in initial cDNA (and hence mRNA levels). Infiltrative C6 glioma cells, therefore, express 32-fold more CXCR4 than core, noninvasive tumor. (c) Infiltrative glioma cells express significantly more CXCR4 message than noninfiltrative tumor cells: graph represents data from four experimental replicates performed as described in (b) (above). Given that C t diff values correspond inversely to gene expression levels, we tabulated our results using 1/C t diff as a quotient for CXCR4 gene expression. As illustrated in the graph, we found significantly higher expression for this gene in infiltrative tumor cells isolated by LCM (1/C t diff ¼ 0.22(70.04)) versus noninvasive glioma cells (1/C t diff ¼ 0.14(70.03)). This difference was statistically significant (P ¼ 0.02, t-test). Glioma cells (U118, U138 and A172 were obtained commercially from ATCC; Manassas, VA. Primary human glioblastoma explants were established and cultured as described previously (Yu et al., 2001) ) were plated on matrigel coated cell culture inserts within a six-well-plate (BD Biosciences). Cell migration was induced along a fetal bovine-serum gradient and invasive cells that translocated through the matrigel matrix and affixed themselves onto the underside of the porous membrane were removed by scraping and collected separately from noninvasive tumor cells that remained within the top chamber. Cells were pooled from a minimum of three replicates for each experimental event. (b) Quantitative real-time PCR (performed and analysed as described in the legend for Figure 1 ) demonstrated that invasive U118 glioma cells expressed 64-fold more CXCL12 message (after normalization against the expression of an 18sRNA internal control gene) than noninvasive tumor (Human CXCL12 specific primers and Taqman probe sequences are proprietary -obtained from Applied Biosystems). Bar graph demonstrates secretion of CXCL12 from in vitro cultured glioma cells. CXCL12 levels in triplicate supernatants were measured using ELISA (R&D Systems; Minneapolis, MN) as previously detailed (Barbero et al., 2003) . reflect in vivo neoplastic cell invasion through an extracellular matrix.
In this report, we now specifically detail that, within individual tumors, CXCR4 overexpressing cells demonstrate enhanced invasive capacity in vitro and in vivo. Our assessment of CXCR4 expression levels was performed using the highly sensitive and readily quantifiable processes of real-time quantitative PCR and flow cytometry. We were able to selectively investigate and quantify chemokine receptor expression levels in infiltrative tumor cells isolated either from in vivo tissues using LCM or from in vitro cultures by specifically analysing only those cells that had invaded through a substrate reflective of in vivo extracellular matrix. In this manner, we detected a significant differential expression of CXCR4, and CXCL12 in one tumor line, between invasive and noninvasive glioma cells. Importantly, neutralization of CXCR4 receptors significantly impaired the in vitro invasive capacity of the CXCR4 expressing tumor lines studied. Given the previously demonstrated capability of CXCR4 antagonists to curtail glioma cell proliferation, it could be possible that the decreased invasion observed by us following CXCR4 neutralization may be contributed by decreased cellular proliferation. However, the 24 h timeline of our in vitro invasion experiments, a timeframe significantly shorter than the 43-98 h cellular doubling times reported earlier for a wide range of in vitro cultured glioma cell lines (Coleman et al., 1980) , argues strongly against simple inhibition of cell growth as a factor accounting for our observed results.
Although the ability of CXCR4 signaling to support neoplastic cell proliferation has been recognized for 0 * * The invasive capacity of various glioma cell lines was assessed quantitatively using a standard in vitro matrigel invasion assay. Prior to seeding, cells were pre-treated with either an anti-CXCR4 IgG (1 mg/ml) known to neutralize receptor function (R&D Systems) or an equivalent concentration of nonspecific isotype matched IgG (BD Pharmingen). At 24 h after seeding, noninvasive cells were removed by scraping and the proportion of cells invading through the matrigel matrix was assessed by staining porous membranes with hematoxylin and eosin. Multiple fields (per single membrane) were counted under a microscope (and normalized against similar fields from nonmatrigel coated control inserts). Our results demonstrated that in vitro neutralization of CXCR4 impaired invasive capacity in three of five cell lines analysed. Primary GBM#2 is the same cell line depicted as Primary GBM in Figure 2 . The inhibition of invasiveness was statistically significant in the case of U118 and Primary GBM#2 (t-test: P ¼ 0.01 and 0.007, respectively). (b) CXCR4 siRNA transfection silences CXCR4 expression in cultured glioma cells: to test an alternate method of abrogating CXCR4 function, we tested whether delivery of gene-specific siRNA could silence expression of CXCR4. We obtained two siRNA duplexes (5 0 -UAAAAUCUUCCUGCCCACCdTdT-3 0 and 5 0 -GGAAGCUG UUGGCUGAAAAdTdT-3 0 ) from Dharmacon (Lafayette, CO). A combination of these two duplexes has been previously shown to effect nearly complete silencing of CXCR4 expression in a human breast cancer cell line (Liang et al., 2005) . Using a documented protocol (Liang et al., 2005) , we transfected cultured glioma cells with a combination of these siRNAs (120 nmol/l each) using Lipofectamine 2000 (Invitrogen; Carlsbad, CA). At 48 h following transfection, we fixed cells with 4% paraformaldehyde and stained using a purified anti-CXCR4 antibody (R&D Systems; Minneapolis, MN) and a Texas-red conjugated secondary antibody (Jackson Immunoresearch; West Grove, PA). Fluorescence microscopy revealed significant silencing of CXCR4 expression on A172 glioma cells, which could not be seen when cells were transfected with a nonspecific, control siRNA duplex. (c) siRNA mediated inhibition of CXCR4 expression blocks glioma cell invasion towards a CXCL12 gradient: we wished to assess the capacity of glioma cells to migrate across a matrigel matrix towards a CXCL12 gradient and the effect that CXCR4 inhibition (neutralizing antibody as well as siRNA) would have on this behavior. As described earlier, we utilized a matrigel invasion assay and pretreated cells by either incubating them with a CXCR4-neutralizing antibody or transfection (48 h prior to this assay) with a combination of two CXCR4-targeted siRNA duplexes. Cells were plated in a top chamber onto a matrigel matrix and were separated from a bottom chamber containing 150 ng/ml of recombinant CXCL12 (R&D Systems; Minneapolis, MN). As described in (a) (above), after 24 h, we microscopically quantitated the proportion of cells that had invaded through the matrigel and affixed themselves to the under-side of the porous membrane. As illustrated, we found that in all gliomas tested there was a marked increase in migratory capacity toward CXCL12 and that CXCR4 inhibition markedly decreased the invasive capacity of tumor cells in the case of the A172 and U87MG cell lines. However, while cells derived from a freshly explanted primary GBM did show increased migratory capacity towards CXCL12 and a modest response following antibody mediated CXCR4 neutralization, no decrease in invasiveness was observed following siRNA transfection. It should be noted however, that our transfection efficiency for delivery of siRNA into primary GBM cells was poor (o20%). We verified the specificity of inhibition in the case of A172 and U87MG by documenting no significant decrease in the invasiveness of these cells following pretreatment with a nonspecific antibody or transfection with control, nonspecific siRNA (not shown). some time, the capacity of this receptor to additionally facilitate tumor cell dispersal is now receiving increased attention. Initial reports described the role of CXCR4 in mediating targeted systemic metastases of breast tumors to sites of endogenous CXCL12 production, such as the brain (Muller et al., 2001) . Recently Bartolome et al. (2004) and Mori et al. (2004) reported that CXCR4 signaling in melanoma and pancreatic cancer, respectively, also contributed to localized tumor cell invasion. This finding may be particularly relevant to glioblastomas, which rarely metastasize systemically. The ability of CXCR4 to mobilize tumor cells has been linked to increased production of effector matrix metalloproteinases (MMPs) (Bartolome et al., 2004; Singh et al., 2004) . MMPs are known to be overexpressed in gliomas and their production, particularly in the case of MMP-9, has been definitively shown to promote tumor cell invasiveness (Lakka et al., 2002 (Lakka et al., , 2004 ). As we have also observed enhanced MMP-9 levels in CXCR4 overexpressing in vivo invasive glioma cells (M Ehtesham; unpublished results), it is possible, therefore, that CXCR4 signaling may mediate glioma cell dispersal directly through upregulation of MMP-9 production. Intriguingly, another recent paper has described the upregulation of MT2-MMP in glioma cells following CXCR4 activation (Zhang et al., 2005) . Additionally, it is known that CXCR4 has a critical interplay with the NF-kB family of transcription factors which are known to promote tumor cell migration through a variety of mechanisms including epithelial to mesenchymal transition (Huber et al., 2004) , increased surface adhesion molecule expression (Wong and Gumbiner, 2003) , MMP production (Woo et al., 2003) , as well as feedback upregulation of CXCR4 (Helbig et al., 2003) . The identification of CXCR4 as a definitive mediator of glioma cell invasiveness, in addition to its previously described role in glioma cell proliferation, adds further importance to the significance of this receptor as a potential target for emerging glioma therapies.
